All lobbying filings

Teva Pharmaceuticals USA, Inc.

Teva Pharmaceuticals USA, Inc. filed a Q2 amendment for Teva Pharmaceuticals USA Inc. on September 4, 2025.

Lobbying for Teva Pharmaceuticals USA Inc.

As filed: TEVA PHARMACEUTICALS USA, INC. for TEVA PHARMACEUTICALS USA INC.

All filings by Teva Pharmaceuticals USA, Inc. · Everything Teva Pharmaceuticals USA Inc. has reported

Filing · LD-2 quarterly report Q2 amendment

Reporting period

2nd Quarter 2025

Apr 1 - June 30 · Posted Sep 4, 2025

Expenses

$1,390,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

New Jersey

Official filing document

Government bodies contacted 9

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Health Issues

Use of Section viii statements in pharmaceutical labeling. Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and legislation to reform pharmacy benefit managers. Patent reform legislation. Proposals related to drug shortages. Reauthorization of the Pandemic and All Hazards Preparedness Act (PAHPA).

Tariff (miscellaneous tariff bills)

A joint resolution terminating the national emergency declared to impose duties on articles imported from Canada (S.J.Res.37).

Bills named in this filing 1

S.J. Res. 37
A joint resolution terminating the national emergency declared to impose duties on articles imported from Canada.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.